...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Blood Medicine >A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists
【24h】

A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists

机译：免疫性血小板减少性紫癜的综述：专注于新型血小板生成素激动剂

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that is characterized by antibody-mediated platelet destruction and decreased platelet production. ITP and its treatments have been recognized to cause diminished quality of life in those afflicted with this illness on levels comparable to other chronic diseases. The disease can be self-limiting, but in adults it often is a chronic process requiring medical intervention to maintain appropriate platelet counts and to reduce bleeding events. Many patients go on to develop disease that is refractory to current interventions. Historically, the aim of treatment has been focused on reducing the amount of antibody-mediated destruction but newer therapies have centered on the decreased platelet production. Two new medications that target production of platelets have recently been USA, Food and Drug Administration (FDA) approved for the treatment of chronic relapsing ITP. Here, we provide an overview of ITP and a comprehensive review of the newest therapies aimed at the stimulation of platelet production.
机译：摘要：免疫性血小板减少性紫癜（ITP）是一种自身免疫性疾病，其特征在于抗体介导的血小板破坏和血小板生成减少。人们已经认识到，ITP及其治疗方法可导致患有这种疾病的人们的生活质量下降，其水平可与其他慢性疾病相提并论。该疾病可以是自限性的，但是在成人中，它通常是一个慢性过程，需要进行医学干预以维持适当的血小板计数并减少出血事件。许多患者继续发展目前的干预措施难以治愈的疾病。从历史上看，治疗的目标一直集中在减少抗体介导的破坏上，但是新的治疗方法集中在血小板生成的减少上。美国最近已批准了两种针对血小板生成的新药，美国食品药品监督管理局（FDA）已批准用于治疗慢性复发性ITP。在这里，我们提供了ITP的概述以及旨在刺激血小板生成的最新疗法的全面综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号